PBLS (Parabilis Medicines) EV-to-EBIT: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $30.38
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Parabilis Medicines's Enterprise Value is $4,254.50 Mil. Parabilis Medicines does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's EV-to-EBIT at this moment.

The historical rank and industry rank for Parabilis Medicines's EV-to-EBIT or its related term are showing as below:

PBLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.55   Med: 0   Max: 0
Current: -29.47
PBLS's EV-to-EBIT is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 12.945 vs PBLS: -29.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Parabilis Medicines's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. Parabilis Medicines does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's Earnings Yield (Joel Greenblatt) % at this moment.

Parabilis Medicines  (NAS:PBLS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Parabilis Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

Parabilis Medicines EV-to-EBIT Related Terms

Parabilis Medicines EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines EV-to-EBIT Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: EV-to-EBIT Comparison

For the Biotechnology subindustry, Parabilis Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's EV-to-EBIT falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines EV-to-EBIT Calculation

Parabilis Medicines's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4254.499/
=

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.38
Price